VRTX
Vertex Pharmaceuticals Incorporated
$538.60−4.02 (−0.74%)Close Nov 13, 2026
Insider trading
12 months to Nov 10, 2026- Sold
- $164M
- 13 insiders
- Largest seller
- $60.9M
- Jeffrey M. Leiden · 37% of sales
- Plan sales
- $164M
- 100% of sales
- Latest buy
- Aug 6, 2025
- Reshma Kewalramani
Buys and sales on the price
Since 2003By period
Open-market trades| Trades | 3 months | 12 months | Since 2003 |
|---|---|---|---|
| Buys | 0 | 0 | 27 |
| Sales | 1 | 59 | 1,763 |
| Plan sales | 1 | 59 | 1,720 |
| Shares bought | 00 | 00 | 332,840333K |
| Shares sold | 11,86611.9K | 354,230354K | 15,669,90015.7M |
| Net shares | −11,866−11.9K | −354,230−354K | −15,337,060−15.3M |
| Net value | −$6.31M | −$164M | −$1.93B |
Insiders
| Insider | 12 months | Shares held |
|---|---|---|
Reshma Kewalramani CEO & President, Director | −44.7% | 86,471 |
Amit Sachdev EVP Chief Patient & Ext Af Off | −87.2% | 74,031 |
Ourania Tatsis EVP, Chief Reg. & Quality Off. | −26.7% | 53,572 |
Charles F. Wagner Jr EVP, CO & FO | −45.5% | 47,042 as of Feb 26, 2026 |
Bruce I. Sachs Director | — | 39,000 |
Trades
1,790 trades since 2003| Type | Insider | Role | Shares | Price | Held after | |||
|---|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | Plan sale | Reshma KewalramaniCEO & President, Director CEO & President, Director | CEO & President, Director | 11,866 at $531.53 | $531.53 | $6.31M | −12.1% 86.5K after | 86,471 |
| Jul 2, 2026 | Plan sale | Ourania TatsisEVP, Chief Reg. & Quality Off. EVP, Chief Reg. & Quality Off. | EVP, Chief Reg. & Quality Off. | 1,500 at $524.99 | $524.99 | $787K | −3.2% 45.3K after | 45,321 |
| Jul 2, 2026 | Plan sale | Duncan McKechnieEVP, Chief Commercial Officer EVP, Chief Commercial Officer | EVP, Chief Commercial Officer | 1,541 at $519.00 | $519.00 | $800K | −12.3% 11.0K after | 11,001 |
| Jul 1, 2026 | Plan sale | Joy LiuEVP and Chief Legal Officer EVP and Chief Legal Officer | EVP and Chief Legal Officer | 828 at $502.71 | $502.71 | $416K | −4.1% 19.1K after | 19,131 |
| Jun 26, 2026 | Plan sale | Carmen BozicEVP and CMO EVP and CMO | EVP and CMO | 596 at $482.50 | $482.50 | $288K | −3.7% 15.3K after | 15,337 |
| Jun 18, 2026 | Plan sale | Carmen BozicEVP and CMO EVP and CMO | EVP and CMO | 1,020 at $462.17 | $462.17 | $471K | −6.0% 15.9K after | 15,933 |
| Jun 15, 2026 | Plan sale | Carmen BozicEVP and CMO EVP and CMO | EVP and CMO | 4,062 at $450.00 | $450.00 | $1.83M | −19.3% 17.0K after | 16,953 |
| Jun 5, 2026 | Plan sale | Carmen BozicEVP and CMO EVP and CMO | EVP and CMO | 1,745 at $450.00 | $450.00 | $785K | −7.7% 21.0K after | 21,015 |
| Jun 1, 2026 | Plan sale | Joy LiuEVP and Chief Legal Officer EVP and Chief Legal Officer | EVP and Chief Legal Officer | 828 at $439.91 | $439.91 | $364K | −4.0% 20.0K after | 19,959 |
| May 29, 2026 | Plan sale | Carmen BozicEVP and CMO EVP and CMO | EVP and CMO | 1,974 at $450.00 | $450.00 | $888K | −8.0% 22.8K after | 22,760 |
- Reshma Kewalramani$6.31MNov 6, 2026 · Plan sale11,866 at $531.53CEO & President, Director−12.1% of holdings, 86.5K after
- Ourania Tatsis$787KJul 2, 2026 · Plan sale1,500 at $524.99EVP, Chief Reg. & Quality Off.−3.2% of holdings, 45.3K after
- Duncan McKechnie$800KJul 2, 2026 · Plan sale1,541 at $519.00EVP, Chief Commercial Officer−12.3% of holdings, 11.0K after
- Joy Liu$416KJul 1, 2026 · Plan sale828 at $502.71EVP and Chief Legal Officer−4.1% of holdings, 19.1K after
- Carmen Bozic$288KJun 26, 2026 · Plan sale596 at $482.50EVP and CMO−3.7% of holdings, 15.3K after
- Carmen Bozic$471KJun 18, 2026 · Plan sale1,020 at $462.17EVP and CMO−6.0% of holdings, 15.9K after
- Carmen Bozic$1.83MJun 15, 2026 · Plan sale4,062 at $450.00EVP and CMO−19.3% of holdings, 17.0K after
- Carmen Bozic$785KJun 5, 2026 · Plan sale1,745 at $450.00EVP and CMO−7.7% of holdings, 21.0K after
- Joy Liu$364KJun 1, 2026 · Plan sale828 at $439.91EVP and Chief Legal Officer−4.0% of holdings, 20.0K after
- Carmen Bozic$888KMay 29, 2026 · Plan sale1,974 at $450.00EVP and CMO−8.0% of holdings, 22.8K after